Salute e Benessere
Neuraxpharm continues international expansion with launch of Neuraxpharm Australia
SYDNEY and DÜSSELDORF, Germany , July 21, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed Head of Commercial, Avendran Naidu, as the Company continues to expand globally.
The launch of Neuraxpharm Australia continues the Company's international growth strategy following the opening last year of Neuraxpharm Middle East and the establishment of affiliates in Brazil and Mexico in 2023. Neuraxpharm Australia will be based in Sydney and reflects Neuraxpharm's intention to market its CNS products across Australia over the coming years.
Neuraxpharm Australia will commercialise the prescription brands Nuvigil (armodafinil) and Modavigil (modafinil), both indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy, which were acquired by Neuraxpharm in December 2024 .
The Australian affiliate will also bring to market BRIUMVI (ublituximab) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) after receiving approval from Australia's Therapeutic Goods Administration (TGA) in June 2025 . Following a positive recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC) at its May 2025 meeting , Neuraxpharm is now working to ensure eligible Australian patients can access BRIUMVI as soon as possible.
Ublituximab, developed by TG Therapeutics and licensed by Neuraxpharm ex-US , is a novel anti-CD20 monoclonal antibody approved in the United States , the European Union, UK and Switzerland for the treatment of adult patients with RRMS that can be administered in a one-hour infusion, twice a year, following the starting dose. Additional leading CNS treatments from Neuraxpharm's portfolio are expected to follow.
Neuraxpharm Australia will be led by Avendran Naidu, the affiliate's newly appointed Head of Commercial. Avendran has more than 15 years of commercial sales and leadership experience in the pharmaceutical industry focusing on neuroscience, having worked on established and launched brands at companies including Jazz Pharmaceuticals ANZ ( Australia & New Zealand ), Teva Pharmaceuticals and Ferring Pharmaceuticals.
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 40 years.
Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships and acquisitions.
The company has c.1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe , two in Latin America , one in the Middle East , one in Australia , and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira.
Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain .
For more information, please visit https://www.neuraxpharm.com
View original content:https://www.prnewswire.co.uk/news-releases/neuraxpharm-continues-international-expansion-with-launch-of-neuraxpharm-australia-302509677.html